Table 4

Multivariable adjusted primary and secondary outcomes

TAPNo-TAPRatio (95% CI of
the ratio)*		P value†‡
Roux-en-Y gastric bypass surgery
Mean (95% CI) estimated opioid analgesia in MME§
 Total opioid administered188 (161 to 218)209 (181 to 242)0.89 (0.81 to 0.99)0.02
 Postoperative opioids administered on request46 (33 to 62)57 (42 to 76)0.80 (0.68 to 0.99)0.02
Median (95% CI) nausea/vomiting treatments n¶
 Antiemetic doses8 (7 to 10)9 (8 to 11)0.85 (0.75 to 1.02)0.06
 Mean (95% CI) length of hospitalization in hours**38 (31 to 45)61 (53 to 72)0.61 (0.52 to 0.74)<0.01
Gastric sleeve surgery
Mean (95% CI) estimated opioid analgesia in MME§
 Total opioid administered186 (164 to 210)205 (182 to 231)0.91 (0.84 to 0.98)<0.01
 Postoperative opioids administered on request61 (44 to 78)71 (54 to 88)0.85 (0.75 to 0.99)0.02
Median (95% CI) nausea/vomiting treatments n¶
 Antiemetic doses9 (8 to 10)10 (9 to 11)0.89 (0.82 to 0.97)<0.01
 Mean length of hospitalization (IQR) in hours**45 (41 to 49)50 (47 to 54)0.89 (0.82 to 0.98)0.02

  • *Ratio of TAP/no-TAP and 95% CI of the ratio.

  • †P value compares TAP to no-TAP group.

  • ‡Adjusted values estimated using generalized mixed effect model with opioid administered and length of stay using a log-normal distribution and number of antiemetic doses a Poisson distribution.

  • §Opioid consumption adjusted for age, anxiety, depression, duration of surgery, gender, history of chronic pain, preoperative opioid use, obstructive sleep apnea, race, and remifentanil use.

  • ¶Antiemetic doses adjusted for age, anxiety, current smoker, duration of surgery, gender, and total opioid administered.

  • ** Length of stay adjusted for age, gender, month of study, and race.

  • IQR, interquartile range (first to third quartile); MME, mg morphine equivalents (oral); TAP, transversus abdominis plane block.